Compare PLAY & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLAY | OABI |
|---|---|---|
| Founded | 1982 | 2012 |
| Country | United States | United States |
| Employees | N/A | 89 |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 387.3M | 391.4M |
| IPO Year | 2011 | N/A |
| Metric | PLAY | OABI |
|---|---|---|
| Price | $9.90 | $2.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | ★ $23.83 | $4.50 |
| AVG Volume (30 Days) | ★ 1.5M | 575.5K |
| Earning Date | 06-09-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.57 | $52.42 |
| Revenue Next Year | $5.00 | $64.69 |
| P/E Ratio | $60.94 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.40 | $1.32 |
| 52 Week High | $33.30 | $2.79 |
| Indicator | PLAY | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 42.51 | 43.00 |
| Support Level | $9.50 | $1.98 |
| Resistance Level | $10.85 | $2.13 |
| Average True Range (ATR) | 0.68 | 0.15 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 33.10 | 21.77 |
Dave & Buster's Entertainment Inc is an owner and operator of entertainment and dining venues in North America that offer experiences for both adults and families under the Dave & Buster's and Main Event brands. The company combines various forms of entertainment, including games, bowling, and watching live sports and other televised events, with a full menu of entrees and appetizers and a selection of alcoholic and non alcoholic beverages, all in one location. Its concept focuses on providing customers the opportunity to Eat, Drink, Play, and Watch, appealing to a balanced mix of adults, families, and teenagers. The company also operates internationally in the early stage as a franchisor of the Dave & Buster's brand.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.